Clin Exp Otorhinolaryngol.  2021 May;14(2):145-146. 10.21053/ceo.2021.00458.

Can We Conquer Advanced Head and Neck Cancer? Current Status and Future Directions

• Won HR
• Koo BS

• KMID: 2515425
• DOI: http://doi.org/10.21053/ceo.2021.00458

Reference

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; Feb. 4. [Epub]. https://doi.org/10.3322/caac.21660.

2. Pulte D, Brenner H. Changes in survival in head and neck cancers in the late 20th and early 21st century: a period analysis. Oncologist. 2010; 15(9):994–1001.

3. Lee YG, Kang EJ, Keam B, Choi JH, Kim JS, Park KU, et al. Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13-01). BMC Cancer. 2020; Aug. 20(1):813.

4. Park JO, Park YM, Jeong WJ, Shin YS, Hong YT, Choi IJ, et al. Survival benefits from surgery for stage IVa head and neck squamous cell carcinoma: a multi-institutional analysis of 1,033 cases. Clin Exp Otorhinolaryngol. 2021; May. 14(2):225–34.

5. Rivera F, Garcia-Castano A, Vega N, Vega-Villegas ME, GutierrezSanz L. Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial. Expert Rev Anticancer Ther. 2009; Oct. 9(10):1421–8.

6. Harrington KJ, Ferris RL, Blumenschein G Jr, Colevas AD, Fayette J, Licitra L, et al. Nivolumab versus standard, single-agent therapy of investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related qualityof-life results from a randomised, phase 3 trial. Lancet Oncol. 2017; Aug. 18(8):1104–15.

7. Burtness B, Harrington KJ, Greil R, Soulieres D, Tahara M, de Castro G Jr, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet. 2019; Nov. 394(10212):1915–28.